Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 5280723
Molecular formula: C20H34O5
IUPAC: 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
Source: PC-ALPROSTADIL
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Nonpeptide prostaglandin E1 with vasodilating/smooth-muscle-relaxing effects.
Evidence and critical reading
Reported scientific and empirical uses
Sexual function · Cardiovascular and vascular function
Caverject is authorized for erectile dysfunction with a specific product/route; other contexts/formulations exist.
Human evidence
Do not confuse a regulated indication with approval of supplier powder. Individual label titration does not become a subcutaneous wellness regimen.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
Do not confuse a regulated indication with approval of supplier powder. Individual label titration does not become a subcutaneous wellness regimen.
Do not confuse a regulated indication with approval of supplier powder. Individual label titration does not become a subcutaneous wellness regimen.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: Caverject is indicated for erectile dysfunction with defined formulation/route/conditions. Authorization is not attributed to catalog powder/labels.
Adverse effects and unknowns
Priapism, fibrosis and pain; certain priapism-predisposing disorders and deformities are contraindications. Anticoagulants increase local bleeding risk.
Contraindications
Caverject: priapism predisposition (e.g., sickle-cell disease, multiple myeloma or leukemia), certain deformities/implants per label.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Anticoagulants including warfarin/heparin can increase local bleeding. Do not extrapolate compatibility from other routes.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Alprostadil · 213 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT05568745 · Balloon + Oxytocin Versus Oral Misoprostol to Induce Labor in Case of PROM (RUBAPRO2)Registry status: TerminatedLast update posted: October 15, 2026Query verification: October 16, 2026
NCT07739121 · Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment RecommendationsRegistry status: RecruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT03720613 · Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced ConstipationRegistry status: RecruitingLast update posted: September 30, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-ALPROSTADIL
PubChem alprostadil (CID 5280723)
October 16, 2026
- REG-CAVERJECT
DailyMed: CAVERJECT alprostadil
October 16, 2026
- SEARCH-PUBMED-alprostadil
PubMed/MED targeted search: TITLE:alprostadil AND TITLE:erectile
October 16, 2026